Literature DB >> 17492900

Gene therapy applications for the treatment of neuropathic pain.

James R Goss1, William F Goins, Joseph C Glorioso.   

Abstract

Neuropathic pain is notoriously difficult to treat; currently available pharmaceutical drugs result in moderate analgesia in approximately a third of patients. As our understanding of the biological processes involved in the establishment and maintenance of neuropathic pain increases, so does the development of novel treatment options. Significant advancements have been made in the past few years in gene transfer, a very powerful potential therapy that can be used to directly target affected areas of the neuraxis or body tissues involved in neuropathic pain. Candidate gene products include directly analgesic proteins as well as proteins that interfere with pain-associated biochemical changes in nerve or other tissues underlying the disease process.

Entities:  

Mesh:

Year:  2007        PMID: 17492900     DOI: 10.1586/14737175.7.5.487

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  9 in total

Review 1.  Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.

Authors:  Ryan G Soderquist; Melissa J Mahoney
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

2.  Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: Bonica lecture, ASRA 2010.

Authors:  Srinivasa N Raja
Journal:  Reg Anesth Pain Med       Date:  2012 Mar-Apr       Impact factor: 6.288

3.  Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats.

Authors:  Tsuyoshi Majima; Yasuhito Funahashi; Shun Takai; William F Goins; Momokazu Gotoh; Pradeep Tyagi; Joseph C Glorioso; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2015-08-31       Impact factor: 5.695

Review 4.  Pathological and protective roles of glia in chronic pain.

Authors:  Erin D Milligan; Linda R Watkins
Journal:  Nat Rev Neurosci       Date:  2009-01       Impact factor: 34.870

5.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Authors:  W F Goins; J R Goss; M B Chancellor; W C de Groat; J C Glorioso; N Yoshimura
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

6.  Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.

Authors:  Ellen C Dengler; Juewen Liu; Audra Kerwin; Sergio Torres; Clara M Olcott; Brandi N Bowman; Leisha Armijo; Katherine Gentry; Jenny Wilkerson; James Wallace; Xingmao Jiang; Eric C Carnes; C Jeffrey Brinker; Erin D Milligan
Journal:  J Control Release       Date:  2013-03-18       Impact factor: 9.776

Review 7.  Spinal interleukin-10 therapy to treat peripheral neuropathic pain.

Authors:  Erin D Milligan; Kathryn R Penzkover; Ryan G Soderquist; Melissa J Mahoney
Journal:  Neuromodulation       Date:  2012-06-01

8.  Interleukin-4 mediates the analgesia produced by low-intensity exercise in mice with neuropathic pain.

Authors:  Franciane Bobinski; Juliana Maia Teixeira; Kathleen Anne Sluka; Adair Roberto Soares Santos
Journal:  Pain       Date:  2018-03       Impact factor: 7.926

9.  Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain.

Authors:  Ellen C Dengler; Lauren A Alberti; Brandi N Bowman; Audra A Kerwin; Jenny L Wilkerson; Daniel R Moezzi; Eugene Limanovich; James A Wallace; Erin D Milligan
Journal:  J Neuroinflammation       Date:  2014-05-21       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.